Clinical Efficacy
Octaplasma® has been studied in both adults and children across a variety of clinical settings
Efficacy and tolerability of Octaplasma® in intensive care patients
Single dose of solvent detergent-treated plasma (Octaplasma®) was administered to patients who were postoperatively admitted to the intensive care unit due to disseminated intravascular coagulation and/or coagulopathy resulting from blood volume dilution or loss.
Efficacy and safety of Octaplasma® in liver transplant
Several Randomized Controlled Studies Have Compared Octaplasma® with FFP in Patients with Severe Coagulopathy or DIC Associated with Liver Disease and Liver Transplantation.
Efficacy and safety of Octaplasma® in cardiac surgery.
Several studies have evaluated the efficacy and safety of Octaplasma® in patients undergoing open heart surgery
Safety and tolerability of Octaplasma® in severe sepsis
Safety and tolerability of Octaplasma® in children with severe sepsis was assessed in two clinical studies. Both studies demonstrated that Octaplasma® is safe for use in children with minimal adverse events.
Safety and Efficacy of Octaplasma® in Thrombotic Microangiopathy
There is good experience with the use of Octaplasma® for Plasma Exchange in TTP within the Canadian healthcare system and studies demonstrate the efficacy and safety of use of Octaplasma® in this setting.
Safety and Efficacy of Octaplasma® in Paediatric Patients
The clinical efficacy of Octaplasma® has been established in paediatric patients in a broad spectrum of indications, including pre- and post-surgical bleeding, those at high risk of bleeding, coagulopathy associated with liver disease, liver or cardiac surgery, and during TPE procedures for hematological disorders and or malignant diseases.
